A randomized, phase II study of GW786034 (pazopanib) in stage D0 relapsed androgen sensitive prostate cancer following limited GnRH [gonadotropin-releasing hormone] agonist therapy.
Phase of Trial: Phase II
Latest Information Update: 16 Feb 2016
At a glance
- Drugs Pazopanib (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 01 Mar 2012 Results published in Prostate Cancer and Prostatic Diseases.
- 16 Aug 2011 Actual end date (December 2010) added as reported by ClinicalTrials.gov.